Revvity Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Revvity Inc trades at $115.28 (market cap $12.91B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.25. The key difference: Revvity Inc pays a 0.24% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Revvity Inc is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | SPHD | |
|---|---|---|
Market Cap | $12.91B | — |
Sector | Technology | — |
52-Week High | $117.75 | $53.55 |
52-Week Low | $82.26 | $46.96 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
SPHD trades at $52.26, down 0.29% today, with a bullish technical signal supported by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income. Recent news highlights investor interest in dividend and value strategies amid market volatility, with articles from Zacks and 24/7 Wall Street in August 2026 emphasizing its role in retirement portfolios.
The outlook for SPHD is stable, appealing for income-focused investors seeking lower volatility. Key opportunities include consistent dividends and defensive positioning, while risks involve interest rate sensitivity and potential underperformance in strong bull markets. Analyst sentiment is generally positive for its strategy in current conditions.
Trailing returns across standard periods
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →